<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2902245010
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RECOTHROM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Thrombin alfa
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store between (2°C – 25°C)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        354.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Italia S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Italia S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 416]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Arabian Health Care Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAXTER HEALTHCARE CORPORATION
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>What RECOTHROM is</u></strong></p><p>RECOTHROM is thrombin that has been developed in the laboratory. It is very similar to thrombin that occurs naturally in human blood. When RECOTHROM solution comes into contact with blood it helps clotting, and bleeding will stop.</p><p>&nbsp;</p><p><strong><u>What RECOTHROM is used for</u></strong></p><p>The active substance of RECOTHROM is recombinant human thrombin. It belongs to a group of medicines called topical hemostats. RECOTHROM is used during surgery to stop local bleeding (this is called hemostasis) on the surface of the bleeding tissue of your body. It may be used by itself or with an absorbable sponge.</p><p>&nbsp;</p><p><strong><u>When RECOTHROM should not be used:</u></strong></p><p>RECOTHROM must NOT be:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injected directly into the bloodstream. For Topical Use Only.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used if you are allergic (hypersensitive) to RECOTHROM or any of the other ingredients of RECOTHROM or hamster protein</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used for the treatment of severe bleeding.</p><p>&nbsp;</p><p>There is a risk of blood clots forming if RECOTHROM enters into the blood stream.</p><p>&nbsp;</p><p>In severe cases, formation of blood clots could interrupt blood flow.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will not give you RECOTHROM:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RECOTHROM must not be injected into blood vessels (veins or arteries). As RECOTHROM forms a clot at the administration site, injection into a blood vessel may result in the formation of blood clots. If these clots are washed into the bloodstream, they may cause life-threatening complications.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have massive or brisk arterial bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of hypersensitivity to RECOTHROM thrombin or any components of RECOTHROM (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have known hypersensitivity to hamster proteins.</p><p>&nbsp;</p><p>If any of the above applies to you, please inform your doctor, surgeon or anaesthetist before you are treated with this medicine.</p><p>&nbsp;</p><p><strong>Warnings and Precautions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:575px"><tbody><tr><td style="vertical-align:top"><p><strong>Serious Warnings and Precautions</strong></p><p>&nbsp;</p><p>Do not inject RECOTHROM directly into the bloodstream. Intravascular injection of thrombin-containing hemostats may result in life-threatening intravascular coagulation or death.</p></td></tr></tbody></table><p>&nbsp;</p><p>Talk to your doctor, nurse or pharmacist before being given RECOTHROM.</p><p>&nbsp;</p><p><strong>Your doctor will take special care with this medicine: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; because RECOTHROM thrombin may cause thrombosis if it enters the circulatory system. Apply topically. DO NOT INJECT.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reactions, including anaphylaxis, may occur.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to snake or hamster protein or any of the ingredients in RECOTHROM listed in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant, are trying to become pregnant or are a nursing mother.</p><p>&nbsp;</p><p><strong>Other medicines and RECOTHROM: </strong></p><p>&nbsp;</p><p>None known.</p><p>&nbsp;</p><p>See also section 1: When RECOTHROM should not be used, and section 4: Possible side effects</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>RECOTHROM with food and drink</strong></p><p>&nbsp;</p><p>Please ask your doctor. Your doctor will decide if you are allowed to eat and drink before the application of RECOTHROM.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>You will only be given RECOTHROM whilst you are pregnant if the benefit outweighs the risk, as there is no available data of use in pregnant women.</p><p><br />&nbsp;</p><p>As it is not known if RECOTHROM is excreted in human milk, you should avoid breast feeding after an operation if you were given RECOTHROM.</p><p>&nbsp;</p><p>Consult your doctor or surgeon if you are pregnant, might be pregnant, or if you are breast-feeding. Your doctor will decide if RECOTHROM may be used during pregnancy or breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>RECOTHROM will ALWAYS be for topical use only. DO NOT INJECT.</p><p>&nbsp;</p><p>RECOTHROM will ALWAYS be administered to you by a surgeon. They will decide on the dose you will receive, depending on your age and the type of operation you are having.</p><p>&nbsp;</p><p>The doctor treating you will apply RECOTHROM solution by itself or with a sponge during surgery. The doctor will apply the solution to stop the bleeding. If a sponge has been used and not removed, it will dissolve and be absorbed after the treatment. The dose depends on the wound to be treated.</p><p>&nbsp;</p><p>The volume of reconstituted RECOTHROM required will vary, depending on the size and number of bleeding sites to be treated and the method of application. The healthcare professional should determine the number of vials required to produce a sufficient volume of reconstituted product.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you have too much RECOTHROM</strong></p><p>A maximum dose of topically applied RECOTHROM has not been established. In clinical studies, the maximum volume administered was 48 mL.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>In rare cases you may develop antibodies against RECOTHROM. These are not expected to be associated with any side effects.</p><p>&nbsp;</p><p>No serious side effects with RECOTHROM were observed.</p><p>&nbsp;</p><p>This is not a complete list of side effects. For any unexpected effects while taking RECOTHROM contact your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>&nbsp;</p><p>By reporting side effects you can help provide more information on the safety of this medicine. If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.</p><p>&nbsp;</p><p>Store at 2&deg;C to 25&deg;C.</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Reconstituted solutions of RECOTHROM prepared with sterile 0.9% sodium chloride, USP, may be stored for up to 24 hours at 2&deg;C to 25&deg;C. Discard reconstituted solution after 24 hours.</p><p>&nbsp;</p><p>Do not use RECOTHROM after the expiry date that is printed on the label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is &alpha;-thrombin.</p><p>&nbsp;</p><p>The inactive ingredients (excipients) are: Histidine, Mannitol, Sucrose, Sodium chloride, Polyethylene glycol 3350, and Calcium chloride dihydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                RECOTHROM Thrombin topical (Recombinant) kit is supplied in single-use, preservative-free vials in the following packages:

Recothrom 5,000 IU:
-	8-mL vial of RECOTHROM 5,000 IU
-	5-mL prefilled diluent syringe (containing sterile 0.9% sodium chloride, USP)
-	sterile needle-free transfer device
-	5-mL sterile empty syringe
-	pre-printed label.

Recothrom 20,000 IU:
-	20-mL vial of RECOTHROM 20,000 IU
-	20-mL vial of diluent (containing sterile 0.9% sodium chloride, USP)
-	2 sterile needle-free transfer device
-	20-mL sterile empty syringe
-	pre-printed label.


No RECOTHROM kit components contain latex.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORISATION HOLDER</strong></p><p>&nbsp;</p><p><strong>Baxter Healthcare Corporation </strong></p><p>60015 Deerfield, IL USA</p><p><strong>&nbsp;</strong></p><p><strong>MANUFACTURER</strong></p><p>&nbsp;</p><p><strong>Patheon Italia S.p.A.</strong></p><p>2 Trav. SX Via Morolense 5</p><p>03013 Ferentino (FR), Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong><u>ما دواء ريكوثروم؟</u></strong></p><p dir="RTL">دواء ريكوثروم هو الثرومبين الذي تم تطويره في المختبر، وهو مشابه جدًا للثرومبين الذي يحدث بشكل طبيعي في دم الإنسان. عندما يتلامس محلول ريكوثروم مع الدم فإنه يساعد على تخثر الدم ويتوقف النزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ما دواعي استعمال ريكوثروم؟</u></strong></p><p dir="RTL">المادة الفعّالة للريكوثروم هي الثرومبين البشري المؤتلف. وينتمي ريكوثروم إلى مجموعة من الأدوية تسمى الهيموستات الموضعية. يُستخدم ريكوثروم أثناء الجراحة لوقف النزيف الموضعي (ويُطلق عليه الإرقاء) على سطح الأنسجة النازفة في جسمك. ويمكن استخدامه مباشرة على الجسم أو بوضعه على إسفنجة قابلة للامتصاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>يجب عدم استعمال ريكوثروم:</u></strong></p><p dir="RTL">يجب عدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقنه مباشرة في مجرى الدم، فهو مخصص للاستخدام الموضعي فقط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم إذا كنت تعاني من حساسية (حساسية شديدة) تجاه ريكوثروم أو أي من المكونات الأخرى للريكوثروم أو بروتين الهامستر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدامه لعلاج النزيف الحاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدامه إذا كان هناك خطر من تكون جلطات الدم إذا دخل ريكوثروم في مجرى الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الحالات الشديدة، يمكن أن يؤدي تكوّن جلطات الدم إلى انقطاع تدفق الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا يعطيك الطبيب</strong> <strong>ريكوثروم في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم حقن ريكوثروم في الأوعية الدموية (الأوردة أو الشرايين). نظرًا إلى أن &rlm;‫ريكوثروم يشكل جلطة في موقع الاستعمال، فقد يؤدي حقنه في الأوعية الدموية إلى تكوين جلطات دموية. إذا وصلت هذه الجلطات إلى مجرى الدم، فقد تسبب مضاعفات تهدد الحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك نزيف شرياني حاد أو سريع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك فرط حساسية معروف مسبقًا تجاه ريكوثروم الثرومبين أو أي من مكونات ريكوثروم (مذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية تجاه بروتينات الهامستر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أي مما سبق، فالرجاء إبلاغ طبيبك أو الجراح أو طبيب التخدير قبل العلاج بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>تحذيرات واحتياطات مهمة</strong></p><p dir="RTL">يجب عدم حقن دواء ريكوثروم مباشرة في مجرى الدم، فقد يؤدي حقن الهيموستات التي تحتوي على الثرومبين داخل الأوعية الدموية إلى تخثر الدم داخل الأوعية الدموية أو الوفاة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك، أو ممرضك، أو الصيدلي قبل إعطائك دواء ريكوثروم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سوف يهتم طبيبك بشكل خاص بهذا الدواء: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظرًا إلى أن ريكوثروم الثرومبين قد يسبب تخثر الدم إذا دخل في الدورة الدموية. استعمل الدواء بشكل موضعي، ولا تحقنه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث تفاعلات فرط الحساسية، وتشمل الحساسية المفرطة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم إذا كنت تعاني من حساسية تجاه بروتينات الهامستر والثعابين أو أي من المكونات الأخرى للريكوثروم المُدرجة في القسم 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً، أو تحاولين الحمل، أو ترضعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وريكوثروم </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروف</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر أيضًا القسم 1: متى يجب عدم استخدام ريكوثروم، والقسم 4: الآثار الجانبية المحتملة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ريكوثروم مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى سؤال طبيبك عن هذا الأمر. سوف يقرر طبيبك ما إذا كان مسموحًا لك أن تأكل وتشرب قبل استعمال دواء ريكوثروم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لن تحصلي على دواء ريكوثروم أثناء الحمل إلا إذا كانت فوائده تفوق مخاطره، حيث لا توجد أي معلومات تخص استخدامه مع النساء الحوامل.</p><p dir="RTL"><br />&nbsp;</p><p dir="RTL">نظرًا إلى أنه من غير المعروف ما إذا كان يتم إفراز ريكوثروم في لبن الأم، فيجب عليكِ تجنب الرضاعة الطبيعية بعد إجراء أي عملية جراحية إذا تم إعطاؤك دواء ريكوثروم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبك أو الجراح إذا كنت حاملاً، أو ربما تكونين حاملاً، أو إذا كنت ترضعين. وسوف يقرر طبيبك ما إذا كان بإمكانك استعمال ريكوثروم أثناء الحمل أو الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الأجهزة والمعدات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينطبق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ريكوثروم دائمًا يكون للاستعمال الموضعي فقط. ولا تحقنه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم دائمًا إعطاؤك ريكوثروم عن طريق الجراح. وسوف يقرر الجراح الجرعة التي ستتلقاها حسب عمرك ونوع العملية التي تجريها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يقوم الطبيب الذي يعالجك بوضع محلول ريكوثروم مباشرة على جسمك أو باستخدام إسفنجة أثناء الجراحة. ويقوم الطبيب باستعمال المحلول لوقف النزيف. إذا تم استخدام الإسفنجة ولم تتم إزالتها، فسوف تذوب وتُمتص بعد العلاج. وتعتمد الجرعة على حجم الجرح المراد علاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يختلف حجم ريكوثروم المُعاد تركيبه حسب حجم وعدد أماكن النزيف المراد علاجها وطريقة استعمال ريكوثروم. ويجب على أخصائي الرعاية الصحية تحديد عدد القنينات المطلوبة لإنتاج حجم كافٍ من المنتج المعاد تركيبه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا حصلت على جرعة كبيرة من ريكوثروم</strong></p><p dir="RTL">لم يتم تحديد الجرعة القصوى من ريكوثروم الذي يُستعمل موضعيًا. وفي الدراسات السريرية، كان الحجم الأقصى المُعطى من ريكوثروم 48 مل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، قد تتكون أجسام مضادة ضد ريكوثروم. ومن غير المتوقع أن تكون مرتبطة بحدوث أي آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يلاحظ حدوث أي آثار جانبية خطيرة مرتبطة بدواء ريكوثروم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه ليست قائمة كاملة بالآثار الجانبية. اتصل بطبيبك أو الصيدلي عند حدوث أي آثار غير متوقعة أثناء تناول دواء ريكوثروم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التفاعلات العكسية المشتبه بها</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء. إذا عانيت من أي آثار جانبية، فتحدث إلى طبيبك أو الممرض أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً من خلال:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>دول الخليج العربي الأخرى:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p dir="RTL">-&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالجهات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في درجة حرارة بين 2 و25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُجمّد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تخزين محاليل ريكوثروم المُعاد تركيبها، والتي تم تحضيرها باستخدام 0.9% من كلوريد الصوديوم المُعقّم، USP، لمدة تصل إلى 24 ساعة عند درجة حرارة تتراوح بين 2 و25 درجة مئوية تجاهل المحلول المُعاد تركيبه بعد 24 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل ريكوثروم بعد تاريخ انتهاء الصلاحية المطبوع على المُلصق. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. سوف تساعد هذه الإجراءات في حماية البيئة.&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي ألفا ثرومبين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المكونات غير الفعّالة (السواغات) هي: الهيستيدين والمانيتول والسكروز وكلوريد الصوديوم وبولي إيثيلين جلايكول 3350 وثنائي هيدرات كلوريد الكالسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">يتم توفير مجموعة ريكوثروم ثرومبين الموضعي (المؤتلف) في قنينات أحادية الاستخدام وخالية من المواد الحافظة في العبوات التالية:</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ريكوثروم </strong><strong>5000</strong><strong> وحدة دولية</strong></p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قنينة سعة<strong> </strong>8 مل من ريكوثروم<strong> </strong>5000 وحدة دولية</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محقنة معبأة مُسبقًا بمادة مخففة سعة 5 مل (تحتوي على<strong> </strong>0.9% من كلوريد الصوديوم المُعقّم،<strong> </strong>USP)</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهاز نقل مُعقّم خالٍ من الإبر</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محقنة فارغة مُعقّمة سعة 5 مل</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُلصق مطبوع مسبقًا</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>ريكوثروم </strong><strong>20000</strong><strong> وحدة دولية</strong></p><p dir="RTL" style="text-align:right"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قنينة سعة<strong> </strong>20<strong> </strong>مل من ريكوثروم<strong> </strong>20000<strong> </strong>وحدة دولية</p><p dir="RTL" style="text-align:right"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قنينة معبأة بمادة مخففة سعة<strong> </strong>20<strong> </strong>مل (تحتوي على 0.9<strong>%</strong> من كلوريد الصوديوم المُعقّم<strong>،</strong> USP)</p><p dir="RTL" style="text-align:right"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>2<strong> </strong>جهاز نقل مُعقّم خالٍ من الإبر</p><p dir="RTL" style="text-align:right"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>محقنة فارغة مُعقّمة سعة 20<strong> </strong>مل</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُلصق مطبوع مسبقًا</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لا تحتوي مكونات مجموعة ريكوثروم على مادة اللاتكس.</p><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>Baxter Healthcare Corporation </strong></p><p dir="RTL">60015 Deerfield, IL USA</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>Patheon Italia S.p.A.</strong></p><p dir="RTL">2 Trav. SX Via Morolense 5</p><p dir="RTL">03013 Ferentino (FR), Italy</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RECOTHROM 5,000 IU Thrombin topical (Recombinant)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RECOTHROM Thrombin topical (Recombinant), is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. RECOTHROM is identical in amino acid sequence and structurally similar to naturally occurring human thrombin. RECOTHROM precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic process that yields a product having hemostatic activities similar to native human thrombin. The cell line used to manufacture RECOTHROM has been tested and shown to be free of known infectious agents. The cell culture process used in the manufacture of RECOTHROM employs no additives of human or animal origin. The purification process includes solvent-detergent treatment and nano-filtration steps dedicated to viral clearance.

Each RECOTHROM 5,000 IU Vial contains 1.6 mg ± 0.2 mg α-thrombin

For the full list of excipients, see section 6.1


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilized Powder for Solution – For Topical Use Only
RECOTHROM is provided as a sterile, white to off-white, preservative-free, lyophilized powder in vials for reconstitution with diluent (sterile 0.9% sodium chloride, USP). Reconstitution with the provided diluent, as described [see 4.2], yields a solution with a pH of 6.0 containing 1000 IU/mL of recombinant thrombin for topical use. The formulated product is a clear, colorless solution upon reconstitution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RECOTHROM Thrombin topical (Recombinant), is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age.</p><p>&nbsp;</p><p>RECOTHROM may be used in conjunction with an absorbable gelatin sponge, USP.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>For topical use only.</strong> DO NOT INJECT.</p><p>Do not inject RECOTHROM directly into the bloodstream. Intravascular injection of thrombin-containing hemostats may result in life-threatening intravascular coagulation or death.</p><p>RECOTHROM is for topical use only.</p><p>Apply on the surface of bleeding tissue only.</p><p>&nbsp;</p><p>The volume of reconstituted RECOTHROM required will vary, depending on the size and number of bleeding sites to be treated and the method of application. The healthcare professional should determine the number of vials required to produce a sufficient volume of reconstituted product. The mean volume of RECOTHROM used in the pivotal phase III trial was 11.6 mL.</p><p>&nbsp;</p><p><strong><u>Administration</u></strong></p><p><u>Reconstitution of RECOTHROM Thrombin</u></p><p>The volume of reconstituted RECOTHROM thrombin required will vary depending on the size and number of bleeding sites to be treated and the method of application.</p><p>&nbsp;</p><p>Inspect the integrity of the RECOTHROM package and contents. Do not use if the packaging or contents have been damaged or opened.</p><p>&nbsp;</p><p>Reconstitute the lyophilized powder using the supplied diluent. Use aseptic technique when handling vials and syringes.</p><p><u>5000 IU RECOTHROM Thrombin Reconstitution </u></p><p>Units used herein represent international units of potency determined using a reference standard that has been calibrated against the World Health Organization Second International Standard for Thrombin.</p><ol><li>Remove flip-off cap from the top of the RECOTHROM vial.</li><li>Attach the needle-free transfer device and snap it into place on the vial by placing the vial on a flat surface and attaching the transfer device straight into the center of the vial stopper.</li><li>Attach the prefilled diluent syringe to the needle-free transfer device.</li><li>Inject the 5 mL of diluent from the syringe into the product vial. Keep the syringe plunger depressed.</li><li>DO NOT reuse the diluent syringe for transfer of the reconstituted product. Remove and discard the diluent syringe.</li><li>Gently swirl and invert the product vial until the powder is completely dissolved. Avoid excessive agitation. The powder should dissolve in less than one minute at room temperature.</li><li>Apply the pre-printed &quot;DO NOT INJECT&quot; label to the sterile, empty transfer syringe provided, then draw up the RECOTHROM solution.</li></ol><p>&nbsp;</p><p><u>Application Techniques</u></p><p>Topically apply RECOTHROM thrombin solution directly or in conjunction with absorbable gelatin sponge onto the bleeding site. DO NOT INJECT.</p><p>The amount required depends upon the area of tissue to be treated and the method of application.</p><p>Vials are for single use only. Discard unused contents.</p><p><u>Use with Absorbable Gelatin Sponge</u></p><p>Refer to the absorbable gelatin sponge labeling for safety information and instructions on appropriate use.</p><ol><li>Transfer solution from syringe to a sterile bowl or basin.</li><li>Place the desired size pieces of the absorbable gelatin sponge into the bowl containing reconstituted RECOTHROM to completely saturate the sponge(s).</li><li>Remove the saturated sponge(s) and squeeze gently to remove excess RECOTHROM.</li><li>Apply the sponge to the bleeding site in a single layer.</li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Do not inject directly into the circulatory system. Intravenous administration of RECOTHROM is contraindicated and may result in blood clotting requiring clinical intervention.
•	Do not use for the treatment of massive or brisk arterial bleeding. 
•	Do not administer to patients with a history of hypersensitivity to RECOTHROM thrombin or any components of RECOTHROM.
•	Do not use in patients with known hypersensitivity to hamster proteins. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Serious Warnings and Precautions</strong></p><p>Do not inject RECOTHROM directly into the bloodstream. Intravascular injection of thrombin-containing hemostats may result in life-threatening intravascular coagulation or death.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>4.4.1 &nbsp;&nbsp;&nbsp;Thrombosis </strong></p><p>RECOTHROM thrombin may cause thrombosis if it enters the circulatory system. Apply topically. DO NOT INJECT.</p><p>&nbsp;</p><p><strong>4.4.2&nbsp;&nbsp;&nbsp; </strong><strong>Hypersensitivity Reactions</strong></p><p>Hypersensitivity reactions, including anaphylaxis, may occur.</p><p>RECOTHROM thrombin is produced in a genetically modified Chinese Hamster Ovary (CHO) cell line and may contain hamster or snake proteins [<em>see (2) and (4)</em>].</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions with other drugs, food, herbal preparations, or laboratory tests have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6.1 &nbsp;&nbsp;&nbsp;Pregnancy</strong></p><p>There are no available data regarding RECOTHROM in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with RECOTHROM thrombin.</p><p>&nbsp;</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively</p><p>&nbsp;</p><p><strong>4.6.2 &nbsp;&nbsp;&nbsp;Lactation</strong></p><p>There is no information regarding the presence of RECOTHROM in human milk, the effects on the breastfed infant, and the effects on milk production.</p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for RECOTHROM and any potential adverse effects on the breastfed child from RECOTHROM or from underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Thromboembolic adverse reactions were reported in 6% of surgical patients treated with RECOTHROM thrombin in all completed clinical trials (N=644) <em>[see 4.4]</em>.</p><p>&nbsp;</p><p>Antibody formation to RECOTHROM occurred in &lt;1% of patients. None of the antibodies detected neutralized native human thrombin <em>[see 4.8.2]</em>.</p><p>&nbsp;</p><p><strong>4.8.1 &nbsp;&nbsp;&nbsp;Clinical Trials Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>Clinical trials have been performed with RECOTHROM thrombin applied with absorbable gelatin sponge and applied with a spray applicator. A total of 644 patients were exposed to RECOTHROM in these studies.</p><p>&nbsp;</p><p><u>RECOTHROM Thrombin Used in Conjunction with Absorbable Gelatin Sponge</u></p><p>Four hundred eleven (411) patients were treated in a randomized, double-blind, controlled trial that compared RECOTHROM to bovine thrombin. Both thrombins were applied with a gelatin sponge in patients undergoing spinal surgery, hepatic resection, peripheral arterial bypass surgery, or arteriovenous graft formation for hemodialysis access.<sup>1</sup> The incidence of thromboembolic adverse reactions was similar between the RECOTHROM and bovine thrombin treatment groups (see Table 1).&nbsp;</p><p>&nbsp;</p><p><strong>Table 1: Incidence of Adverse Reactions with RECOTHROM Thrombin and Bovine Thrombin</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction Category</strong></p></td><td style="vertical-align:top"><p><strong>RECOTHROM </strong></p><p><strong>(N=205) </strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Bovine Thrombin*</strong></p><p><strong>(N=206) </strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolic events</p></td><td style="vertical-align:top"><p>11 (5%)</p></td><td style="vertical-align:top"><p>12 (6%)</p></td></tr></tbody></table><p>*THROMBIN-JMI Thrombin, Topical (Bovine)</p><p>&nbsp;</p><p>In an open-label, single-group trial (N=209), patients with documented or highly likely prior exposure to bovine thrombin within the previous three years were treated with RECOTHROM when undergoing surgeries (spinal, peripheral arterial bypass, or arteriovenous graft formation for hemodialysis access).<sup>2</sup> The incidence of thromboembolic adverse reactions in this study was 9%.</p><p>&nbsp;</p><p>In an open-label, single-group trial of re-exposure to RECOTHROM (N=31), patients with documented prior exposure to RECOTHROM were treated with RECOTHROM during surgery (spinal, peripheral arterial bypass, arteriovenous graft formation, or other procedures).<sup>3</sup> The incidence of thromboembolic adverse reactions in this study was 3%.</p><p>&nbsp;</p><p>In other randomized, double-blind trials across a range of surgical settings (N=130; spinal surgery, hepatic resection, peripheral arterial bypass surgery, or arteriovenous graft formation for hemodialysis access), the safety of RECOTHROM (n=88 patients) was compared to placebo (RECOTHROM excipients reconstituted with sterile 0.9% sodium chloride, USP) (n=42 patients). The incidence of thromboembolic adverse reactions in this study was 5% for RECOTHROM and 12% for placebo.&nbsp;</p><p>&nbsp;</p><p><strong>4.8.2 &nbsp;&nbsp;Immunogenicity</strong></p><p>The detection of antibody formation is highly dependent upon the sensitivity and specificity of the assay. The absolute immunogenicity rates reported here are difficult to compare with the results from other products due to differences in assay methodology, patient populations, and other underlying factors.</p><p>&nbsp;</p><p>The potential for development of antibodies to RECOTHROM thrombin was evaluated in multiple clinical trials and included patients with a single exposure to RECOTHROM as well as patients who were re-exposed to RECOTHROM during a subsequent surgical procedure. Only patients with both baseline and post-treatment antibody specimens available were evaluated for the development of specific anti-RECOTHROM product antibodies, which was defined as seroconversion or a &ge;1.0 titer unit (&ge;10-fold) increase in antibody levels after study treatment. Five of 609 (0.8%; 95% CI, 0.4%-2.8%) evaluable patients developed specific anti-RECOTHROM product antibodies. None of these antibodies were found to neutralize native human thrombin. There was no difference in anti-RECOTHROM product antibody formation incidence among patients exposed to RECOTHROM applied with absorbable gelatin sponge, USP or with spray applicator.</p><p>&nbsp;</p><p>In a clinical trial comparing RECOTHROM to bovine thrombin (N=411; n=398 antibody evaluable) for the development of specific anti-product antibodies, blood samples were collected at baseline and at Day 29 in both treatment groups and were analyzed by ELISA.<sup>1</sup> At baseline, 1.5% of RECOTHROM patients (n=3/198) had positive anti-product antibody titers compared with 5% of bovine thrombin patients (n=10/200). Of these patients, none of the RECOTHROM group and eight in the bovine thrombin group exhibited &ge;1.0 titer unit (&ge;10-fold) increases in anti-product antibody levels after study treatment.</p><p>&nbsp;</p><p>At Day 29, three of 198 (1.5%; 95% CI, 0%-4%) patients in the RECOTHROM group developed specific anti-product antibodies (one patient also developed anti-CHO host cell protein antibodies); 43 of 200 patients in the bovine thrombin group (22%; 95% CI, 16%-28%) developed specific antibodies to bovine thrombin product. Treatment with RECOTHROM resulted in a statistically significant lower incidence of specific anti-product antibody development. Because the study was not powered to detect a difference in clinical outcomes attributable to antibody formation, no conclusions can be drawn regarding the clinical significance of the difference in antibody formation based on the results of this study. None of the antibodies in the RECOTHROM group neutralized native human thrombin. Antibodies against bovine thrombin product were&nbsp;not tested for neutralization of native human thrombin.</p><p>&nbsp;</p><p>In a trial of patients with a high likelihood of prior exposure to bovine thrombin, 15.6% of patients (n=32/205) had anti-bovine thrombin product antibodies and 2% of patients (n=4/200) had anti-RECOTHROM product antibodies at baseline.<sup>2</sup> Following treatment, none of the 200 evaluable patients (patients for whom post-treatment specimens were available) developed antibodies to RECOTHROM.</p><p>&nbsp;</p><p>In a trial of patients previously exposed to RECOTHROM, 31 patients were re-exposed to</p><p>RECOTHROM during a subsequent surgery.<sup>3</sup> None of the evaluable patients (n=30) had anti-</p><p>RECOTHROM product antibodies at baseline and none developed antibodies at Day 29.</p><p>&nbsp;</p><p>In a trial of RECOTHROM, including 26 pediatric patients (aged one month to 16 years) and four patients 17 years of age, one patient without prior thrombin exposure had pre-existing anti-RECOTHROM product antibodies at baseline.<sup>5</sup> None of the 27 evaluable patients developed anti-RECOTHROM product antibodies at Day 29.</p><p>&nbsp;</p><p><em><u>Pediatric population</u></em></p><p>A total of 30 pediatric patients, ages 0 to 16 years (one month to 2 years, n=10; 2 to 12 years, n=12; 12 to 16 years, n=8), were treated in clinical trials with RECOTHROM thrombin using a spray applicator to burn wound excision sites prior to autologous skin grafting. No patient experienced a thromboembolic adverse reaction. The safety of RECOTHROM in pediatric patients greater than or equal to one month of age is supported by these data and by extrapolation of efficacy from adequate and well-controlled studies of RECOTHROM in adults.</p><p>&nbsp;</p><p>Safety and efficacy have not been established in neonates.</p><p><strong>&nbsp;</strong></p><p><em><u>Geriatric Use</u></em></p><p>Of 644 patients in clinical studies of RECOTHROM thrombin, 36% (n=232/644) were &ge;65 years old and 15% (n=95/644) were &ge;75 years old.</p><p>&nbsp;</p><p>No differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It&nbsp;allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/ <u>&nbsp;</u>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A maximum dose of topically applied RECOTHROM has not been established. In clinical studies, the maximum volume administered was 48 mL.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Local hemostatics group, thrombin</p><p>ATC code: B02BD30</p><p>&nbsp;</p><p><u>Mechanism of Action:</u></p><p>RECOTHROM Thrombin topical (Recombinant), is a specific human serine protease that promotes hemostasis and acts locally when applied topically to a site of bleeding.</p><p>&nbsp;</p><p>RECOTHROM activates platelets and catalyzes the conversion of fibrinogen to fibrin, which are steps that are essential for blood clot formation.</p><p>&nbsp;</p><p>RECOTHROM was evaluated in a Phase III study conducted in 411 subjects undergoing surgery in 1 of 4 surgical settings: spinal surgery, hepatic segment surgery, peripheral arterial bypass surgery, and arteriovenous graft formation for hemodialysis access. The study was a multiple site, randomized, double-blind, controlled evaluation of RECOTHROM compared to bovine thrombin, each at a nominal concentration of 1000 IU/mL topically applied to bleeding sites with an absorbable gelatin sponge.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>RECOTHROM is intended for topical use only. Intravascular administration is contraindicated (see 4.3 section). As a consequence, intravascular pharmacokinetic studies were not performed in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3.1&nbsp; &nbsp;&nbsp;Nonclinical Toxicology</strong></p><p><strong>&nbsp;</strong></p><p><strong>5.3.1.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p><em>In vitro</em> cytotoxicity studies have been performed in mouse L929 fibroblast cell cultures and demonstrate a concentration-dependent effect on cell morphology. The thrombin-induced morphological changes were similar to those seen with bovine thrombin.</p><p>&nbsp;</p><p><strong>5.3.1.2 Animal Toxicology and/or Pharmacology</strong></p><p>In a study in nonhuman primates, RECOTHROM thrombin was applied directly to a liver wound with an absorbable gelatin sponge, USP. In a second study, RECOTHROM was administered subcutaneously once weekly for four weeks to nonhuman primates following repeat doses of 5405 units/m<sup>2</sup>. In both studies, RECOTHROM had no effect on clinical signs, serum chemistry, coagulation parameters, or histopathology; only normal postsurgical findings were observed. No animals developed anti-RECOTHROM product antibodies in either study.</p><p>&nbsp;</p><p>RECOTHROM was found to be non-irritating when instilled in the eyes (200 units) or applied to normal or abraded skin of rabbits (up to 1000 units/site).</p><p>To evaluate RECOTHROM inhibition and clearance from the bloodstream, radiolabeled RECOTHROM was administered intravenously or subcutaneously to nonhuman primates and applied with an absorbable gelatin sponge, USP, in a rabbit hepatic wound model. RECOTHROM did not circulate in the blood as free, active molecule, but was rapidly inactivated (&lt;5 minutes) after formation of complexes with endogenous inhibitors (e.g., antithrombin III); these complexes were cleared by the liver. RECOTHROM applied with an absorbable gelatin sponge, USP, was shown to decrease time to hemostasis (TTH) when compared to saline in a rabbit hepatic wound model and rat heminephrectomy model. RECOTHROM also reduced TTH when directly applied in a porcine partial-thickness excisional skin-wound model as compared to saline control (or no treatment).</p><p>&nbsp;</p><p>RECOTHROM applied with a gauze sponge decreased TTH in a concentration-dependent manner in both the rabbit and rat models. Concentrations of RECOTHROM &gt;1000 units/mL were no different than 1000 units/mL while the effect of RECOTHROM diluted to a concentration of 100 units/mL on TTH was indistinguishable from placebo.</p><p>&nbsp;</p><p><strong>5.3.2&nbsp; &nbsp;Clinical Studies</strong></p><p>RECOTHROM thrombin was evaluated in a randomized, double-blind comparative clinical trial to bovine thrombin. Each thrombin was topically applied to bleeding sites with an absorbable gelatin sponge at a nominal concentration of 1000 units/mL.<sup>1</sup> Patients (N=411) were a heterogeneous surgical population undergoing surgery in one of four surgical settings: spinal surgery (n=122, 30%), hepatic resection (n=125, 30%), peripheral arterial bypass surgery (n=88, 21%), and arteriovenous graft formation for hemodialysis access (n=76, 18%). Patients with prior heparin-induced thrombocytopenia were excluded. Patient ages ranged from 21 to 89 years, gender was 53% male and 47% female, and the distribution by race was 68% white, 18% black or African American, and 14% other. The distribution of these characteristics was similar in both the RECOTHROM and bovine thrombin treatment groups.</p><p>&nbsp;</p><p>The objectives of the study were to evaluate the comparative efficacy, safety, and immunogenicity of RECOTHROM and bovine thrombin in combination with an absorbable gelatin sponge as adjuncts to hemostasis in surgery. Efficacy was evaluated by the incidence of hemostasis within 10 minutes. Bleeding appropriate for evaluation was defined as mild to moderate bleeding, either on its own or remaining after brisk bleeding was controlled by standard surgical modalities. Although multiple bleeding sites could be treated, only one bleeding site per patient was selected to determine effectiveness.</p><p>&nbsp;</p><p>Table 2 summarizes the incidence of hemostasis within 10 minutes for each treatment for the 401 efficacy evaluable patients. The incidence of hemostasis within 10 minutes was comparable for the RECOTHROM and bovine thrombin groups.</p><p>&nbsp;</p><p><strong>Table 2: Hemostasis Within 10 Minutes*</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>RECOTHROM</strong></p><p><strong>(N=198)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Bovine Thrombin<sup>&dagger;</sup></strong></p><p><strong>(N=203)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>95%</p></td><td style="vertical-align:top"><p>95%</p></td></tr><tr><td style="vertical-align:top"><p>Spinal surgery</p></td><td style="vertical-align:top"><p>98%</p></td><td style="vertical-align:top"><p>98%</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic resection</p></td><td style="vertical-align:top"><p>98%</p></td><td style="vertical-align:top"><p>97%</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral arterial bypass</p></td><td style="vertical-align:top"><p>85%</p></td><td style="vertical-align:top"><p>86%</p></td></tr><tr><td style="vertical-align:top"><p>Arteriovenous graft formation</p></td><td style="vertical-align:top"><p>97%</p></td><td style="vertical-align:top"><p>97%</p></td></tr></tbody></table><p><strong>*</strong>Evaluation of hemostasis at &le; 10 minutes for patients treated at 1 of 4 primary TTH bleeding site types: epidural venous plexus, hepatic resection site, peripheral arterial bypass proximal anastomosis, and arteriovenous graft arterial anastomosis.</p><p><sup>&dagger;</sup>THROMBIN-JMI Thrombin, Topical (Bovine)</p><p>&nbsp;</p><p>The percentage of patients achieving hemostasis at 1.5, 3, 6, and 10 minutes is listed in Table 3.</p><p><strong>&nbsp;</strong></p><p><strong>Table 3: Cumulative Incidence of Hemostasis Over Time</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Time (Minutes)</strong></p></td><td style="vertical-align:top"><p><strong>RECOTHROM</strong></p><p><strong>(N=198)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Bovine Thrombin<sup>*</sup></strong></p><p><strong>(N=203)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>48%</p></td><td style="vertical-align:top"><p>46%</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>72%</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>92%</p></td><td style="vertical-align:top"><p>88%</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>95%</p></td><td style="vertical-align:top"><p>95%</p></td></tr></tbody></table><p>*THROMBIN-JMI Thrombin, Topical (Bovine)</p><p>&nbsp;</p><p><strong>5.3.3&nbsp; &nbsp;References</strong><strong> </strong></p><ol><li>Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256-265.</li><li>Singla NK, Ballard JL, Moneta G, et al. A phase 3b open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg. 2009;209(1):68-74.</li><li>Singla NK, Gasparis AP, Ballard JL, et al. Immunogenicity and safety of re-exposure to recombinant human thrombin in surgical hemostasis. J Am Coll Surg. 2011;213(6):722-727.</li><li>Greenhalgh DG, Gamelli RL, Collins J, et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res. 2009;30(3):371-379.</li><li>Foster KN, Mullins RF, Greenhalgh DG, et al. Recombinant human thrombin: safety and immunogenicity in pediatric burn wound excision. J Ped Surg. 2011;46(10):1992-1999.</li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Histidine, Mannitol, Sucrose, Sodium chloride, Polyethylene glycol 3350, Calcium chloride dihydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at 2&deg;C to 25&deg;C.</p><p>Do not freeze</p><p>&nbsp;</p><p>Reconstituted solutions of RECOTHROM prepared with sterile 0.9% sodium chloride, USP, may be stored for up to 24 hours at 2&deg;C to 25&deg;C.</p><p>Discard reconstituted solution after 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RECOTHROM Thrombin topical (Recombinant) kit is supplied in single-use, preservative-free vials in the following packages:</p><p>&nbsp;</p><p>A 5000 IU vial (8-mL) of RECOTHROM with a 5-mL prefilled diluent syringe (containing sterile 0.9% sodium chloride, USP), a sterile needle-free transfer device, a 5-mL sterile empty syringe, and a pre-printed label.</p><p>&nbsp;</p><p>No RECOTHROM kit components contain latex.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See under section 4.2, Posology and Method of Administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Baxter Healthcare Corporation
60015 Deerfield, IL USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>